Brooks Kuhn, MD
Pulmonary Disease · Sacramento, CANPI 1851528947
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $119,914 of the $187,963 with a category attached, or 63.8%. 19 manufacturers reported payments, led by Takeda Pharmaceuticals U.S.A., Inc. at 34.3% of the total. Among pulmonary disease clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 180 payments — averaging $1044.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Takeda Pharmaceuticals U.S.A., Inc.$64K
- Regeneron Healthcare Solutions, Inc.$53K
- Sanofi$22K
- Grifols USA, LLC$17K
- AstraZeneca$9K
- Mylan Inc.$5K
- plus $18K from 13 others
Across 14 payments — averaging $18,255 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Vertex$177K
- AstraZeneca$79K
What the payments were for
- Consulting fees$53,86329%
- Speaking & faculty fees$119,91464%
- Travel & lodging$10,0495%
- Food & beverage$4,1242%
- Education$130%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 32 | $64,430 |
| Regeneron Healthcare Solutions, Inc. | 63 | $53,282 |
| Sanofi | 9 | $21,561 |
| Grifols USA, LLC | 26 | $16,841 |
| AstraZeneca | 17 | $9,128 |
| Mylan Inc. | 8 | $4,704 |
| Regeneron | 2 | $4,530 |
| Boehringer Ingelheim | 3 | $2,874 |
| Mylan Specialty L.p. | 9 | $2,068 |
| Viatris Specialty LLC | 1 | $2,022 |
| GSK | 2 | $2,003 |
| Verona Pharma, Inc. | 1 | $1,500 |
| Electromed, Inc. | 1 | $1,200 |
| Hill-rom Company, Inc | 1 | $875 |
| Grifols Shared Services North America, Inc. | 1 | $660 |
| Genentech USA, Inc. | 1 | $125 |
| Pulmonx Corporation | 1 | $89 |
| La Jolla Pharmaceutical Company | 1 | $57 |
| Merck | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DUPIXENT$41,973
- GLASSIA$30,021
- Prolastin-C Liquid$12,132
- Yupelri$8,766
- Prolastin-C$5,015
- BREZTRI$3,171
- STIOLTO RESPIMAT$2,795
- FASENRA$1,960
- NUCALA$1,950
- Ohtuvayre$1,500
- SMARTVEST$1,200
- The Monarch Airway Clearance System$875
- The Vest System Model 105 Home Care$875
- The Vest System 205 Acute Care$875
- Esbriet$125
- XOLAIR$125
- Pulmozyme$125
How this compares
$187,963 in reported general payments places this provider in the 95th percentile of 1,261 pulmonary disease providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 288 | $213,722 |
| Dupixent PenDupilumab | 53 | $188,945 |
| XolairOmalizumab | 60 | $174,372 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 46 | $121,656 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 129 | $96,669 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 123 | $82,718 |
| Spiriva RespimatTiotropium Bromide | 111 | $61,539 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 55 | $35,428 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 54 | $29,038 |
| SymbicortBudesonide/Formoterol Fumarate | 71 | $17,995 |
| Advair HfaFluticasone Propion/Salmeterol | 37 | $17,090 |
| Breo ElliptaFluticasone/Vilanterol | 32 | $16,959 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 32 | $13,855 |
| Azithromycin | 408 | $12,403 |
| Roflumilast | 116 | $12,342 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere | $9,128 | $245,572391 claims |
| Boehringer IngelheimStiolto Respimat, Spiriva Respimat, Combivent Respimat | $2,874 | $179,685289 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta, Arnuity Ellipta | $2,003 | $153,724247 claims |
| Grifols USA, LLCProlastin C | $16,841 | $121,65646 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,261 pulmonary disease providers in California.
Other pulmonary disease in Sacramento
- Samuel LouieSacramento$2.8M
- Namita SoodSacramento$227K
- Amir ZekiSacramento$149K
- Mark AvdalovicSacramento$79K
- Shyamsunder SubramanianTracy$1.5M
- Toby MaherLos Angeles$1.3M
- Rajkumar DasguptaPasadena$930K
- Hoang leFountain Valley$814K
- Kevin FussellEncinitas$788K
- Revati ShreeniwasStanford$726K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.